Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
Brigham and Women's Hospital
400 participants
Mar 1, 2023
INTERVENTIONAL
Conditions
Summary
This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.
Eligibility
Inclusion Criteria4
- All patients ≥ 18 years old
- Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology
- Medical history entry, visit diagnosis, or problem list entry of PAD
- Not prescribed LDL-C-lowering therapy
Exclusion Criteria1
- Patients taking a statin, ezetimibe, bempedoic acid, a PCSK9 inhibitor, inclisiran or a combination will be excluded
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
On-screen alert-based decision support raising awareness of need for lipid-lowering therapy in patients with peripheral artery disease
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06300450